Rankings
▼
Calendar
FENC Q4 2023 Earnings — Fennec Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena
FENC
Fennec Pharmaceuticals Inc.
$220M
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$10M
+551.7% YoY
Gross Profit
$9M
93.0% margin
Operating Income
-$2M
-18.7% margin
Net Income
-$3M
-27.6% margin
EPS (Diluted)
$-0.10
QoQ Revenue Growth
+53.6%
Cash Flow
Operating Cash Flow
-$5M
Free Cash Flow
-$5M
Stock-Based Comp.
$857,000
Balance Sheet
Total Assets
$27M
Total Liabilities
$38M
Stockholders' Equity
-$12M
Cash & Equivalents
$13M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$10M
$2M
+551.7%
Gross Profit
$9M
$1M
+541.8%
Operating Income
-$2M
-$6M
+69.5%
Net Income
-$3M
-$8M
+64.6%
← FY 2023
All Quarters
Q1 2024 →